Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab

作者：Sera Toshiki; Hiasa Yoichi; Michitaka Kojiro; Konishi Ichiro; Matsuura Kana; Tokumoto Yoshio; Matsuura Bunzo; Kajiwara Takeshi; Masumoto Toshikazu; Horiike Norio; Onji Morikazu^*

来源：Internal Medicine, 2006, 45(11): 721-724.

DOI：10.2169/internalmedicine.45.1590

• hepatitis B virus
• reactivation
• rituximab

A 59-year-old man developed acute hepatitis with reactivated hepatitis B virus (HBV) following administration of rituximab (anti-CD20 monoclonal antibody). The patient was diagnosed with malignant lymphoma in 1998, and virus marker testing indicated HBV surface antigen (HBsAg)-negative and anti-HBs antibody (anti-HBs)-positive results when chemotherapy including rituximab was started. Levels of aminotransferases were elevated, and HBsAg results turned positive. Despite therapy for late-onset hepatic failure, the patient died. Rituximab appears likely to have induced HBV reactivation in this case. Anti-viral agents should be administered for both HBsAg-positive and anti-HBs-positive patients who are scheduled to receive rituximab.

• 出版日期2006